[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Houghton PJ: Everolimus. Clin Cancer Res; 2010 Mar 01;16(5):1368-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Food and Drug Administration for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial growth factor (VEGF) receptor signaling.
  • Although the target for everolimus, [the serine-threonine kinase mammalian target of rapamycin (mTOR)] is well established, the mechanism by which this agent retards tumor growth is not well defined.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Sirolimus / analogs & derivatives
  • [MeSH-minor] Animals. Clinical Trials as Topic. Everolimus. Humans

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Cell Biol. 2005 Dec;17(6):596-603 [16226444.001]
  • [Cites] Leuk Lymphoma. 2009 Dec;50(12):1916-30 [19757306.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):153-5 [16530700.001]
  • [Cites] Genes Dev. 2008 Jan 15;22(2):239-51 [18198340.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1603-10 [18332469.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13907-17 [11847216.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29655-60 [12777372.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):335-48 [15122205.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3500-7 [15150104.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):519-23 [15193254.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):91-9 [15261145.001]
  • [Cites] Genes Dev. 2004 Dec 1;18(23):2893-904 [15545625.001]
  • [Cites] Nature. 2005 Feb 3;433(7025):477-80 [15690031.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8204-9 [15928081.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1588-95 [18332470.001]
  • [Cites] Lancet. 2008 Aug 9;372(9637):449-56 [18653228.001]
  • [Cites] Clin Cancer Res. 2009 Mar 1;15(5):1612-22 [19223496.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):742-53 [19372546.001]
  • [Cites] Ann Oncol. 2009 Oct;20(10):1674-81 [19549709.001]
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7662-71 [19789339.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4536-41 [19687332.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • (PMID = 20179227.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077776; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P01 CA023099-310011; United States / NCI NIH HHS / CA / CA77776; United States / NCI NIH HHS / CA / R01 CA077776-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  • [Number-of-references] 23
  • [Other-IDs] NLM/ NIHMS167833; NLM/ PMC3003868
  •  go-up   go-down


2. Dokmak S, Cabral C, Couvelard A, Aussilhou B, Belghiti J, Sauvanet A: Pancreatic metastasis from nephroblastoma: an unusual entity. JOP; 2009;10(4):396-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Pancreatic metastasis from renal cell carcinoma is a well-known entity.
  • A nephroblastoma is a frequent childhood cancer but can also occur in adults.
  • After resection, the patient received adjuvant high dose chemotherapy with autologous hematopoietic stem-cell support.
  • After a 21-month follow-up, the patient was in good general condition but had liver recurrence without intra-pancreatic recurrence.
  • A nephroblastoma, like clear cell renal carcinoma, can be considered a possible etiology of pancreatic metastasis from a primary renal tumor.
  • [MeSH-major] Kidney Neoplasms / pathology. Pancreatic Neoplasms / secondary. Wilms Tumor / pathology
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy / methods. Humans. Male. Pancreaticoduodenectomy / methods. Treatment Outcome. Young Adult


3. Cheng YY, Huang L, Lee KM, Li K, Kumta SM: Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer; 2004 May;42(5):410-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines.
  • BACKGROUND: Osteosarcoma is the most common malignant bone tumor of childhood.
  • Significant proportions of these patients eventually develop pulmonary metastases and succumb to their disease even after conventional multi-agent chemotherapy and surgical excision.
  • Bisphosphonates (BPs) have been known to inhibit tumor growth and metastasis in some tumors such as breast cancer, renal cell carcinoma, and prostate cancer, and may do so through inhibition of MMP secretion.
  • We, therefore, tested the effect of BPs on tumor cell invasion, MMP-2 secretion, and apoptosis of osteosarcoma cell lines.
  • PROCEDURE: Two osteosarcoma cell lines (SaOS-2, U(2)OS) were treated with alendronate (50, 100, and 150 microM) for 24 and 48 hr.
  • Matrigel invasion assay was used to investigate the invasive potential of osteosarcoma cell lines before and after alendronate treatment.
  • BP-induced cell apoptosis was evaluated by fluorescent flow cytometric analysis.
  • RESULTS AND CONCLUSIONS: The results showed that alendronate inhibited cell invasion of both osteosarcoma cell lines in a dose-dependent manner.
  • Alendronate reduced the mRNA level and cellular level of MMP-2 in both cell lines in a time and dose-dependent manner.
  • Alendronate also induced significant apoptosis in both cell lines.
  • [MeSH-minor] Apoptosis / drug effects. Cell Culture Techniques / methods. Cell Line, Tumor. Dose-Response Relationship, Drug. Extracellular Matrix Proteins. Humans. RNA / analysis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Hazardous Substances Data Bank. Alendronic acid .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15049011.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; 63231-63-0 / RNA; EC 3.4.24.24 / Matrix Metalloproteinase 2; X1J18R4W8P / Alendronate
  •  go-up   go-down


Advertisement
4. Shnorhavorian M, Friedman DL, Koyle MA: Genitourinary long-term outcomes for childhood cancer survivors. Curr Urol Rep; 2009 Mar;10(2):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genitourinary long-term outcomes for childhood cancer survivors.
  • The treatment of pediatric malignancies represents one of the success stories of modern medicine.
  • There continue to be late toxicities and secondary malignancies of the genitourinary (GU) system for childhood cancer survivors related to the specific therapeutic exposures.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Neoplasms, Second Primary / epidemiology. Urinary Tract / drug effects. Urogenital Neoplasms / epidemiology
  • [MeSH-minor] Carcinoma, Renal Cell / drug therapy. Child. Disease-Free Survival. Dose-Response Relationship, Drug. Health Status. Humans. Kidney Neoplasms / drug therapy. Quality of Life. Radiotherapy Dosage. Survivors. Urinary Bladder Neoplasms

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jul;15(1):99-104 [2968967.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2795-800 [2025844.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1837-44 [2015407.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):668-73 [15390293.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Arch Dis Child. 2003 Jun;88(6):493-6 [12765914.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1926-34 [11283124.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):159-65 [8270973.001]
  • [Cites] Nephrol Dial Transplant. 1999 Jun;14(6):1441-4 [10383005.001]
  • [Cites] Cancer. 1988 Feb 1;61(3):451-7 [3338015.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):1000-3 [7947075.001]
  • [Cites] Am J Nephrol. 1994;14(2):81-4 [8080010.001]
  • [Cites] J Pediatr Oncol Nurs. 1991 Apr;8(2):59 [1675067.001]
  • [Cites] Med Pediatr Oncol. 1997 Jan;28(1):35-40 [8950334.001]
  • [Cites] J Pediatr. 1985 Apr;106(4):659-63 [2984399.001]
  • [Cites] Am J Clin Oncol. 1998 Feb;21(1):58-63 [9499259.001]
  • [Cites] Cancer. 1987 May 1;59(9):1577-81 [3470110.001]
  • [Cites] J Urol. 2001 Oct;166(4):1455-8 [11547111.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Pediatr Blood Cancer. 2004 Mar;42(3):289-91 [14752871.001]
  • [Cites] Pediatr Nephrol. 1999 Feb;13(2):153-62 [10229006.001]
  • [Cites] N Engl J Med. 1988 Apr 21;318(16):1028-32 [3352696.001]
  • [Cites] J Clin Pharmacol. 1999 May;39(5):454-61 [10234592.001]
  • [Cites] Med Pediatr Oncol. 2003 Sep;41(3):190-7 [12868118.001]
  • [Cites] Pediatr Nephrol. 2001 Oct;16(10):796-9 [11605785.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):594-8 [17514733.001]
  • [Cites] Pediatr Blood Cancer. 2004 May;42(5):427-32 [15049014.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2506-13 [12011129.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):295-300 [2056973.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):173-90 [8418231.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(2):121-2 [2910509.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1228-32 [16682132.001]
  • [Cites] J Urol. 2005 Nov;174(5):1972-5 [16217371.001]
  • [Cites] Br J Cancer. 1998 May;77(10):1677-82 [9635848.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1851-9 [7636528.001]
  • [Cites] J Pediatr Oncol Nurs. 2008 Mar-Apr;25(2):97-101 [18353752.001]
  • (PMID = 19239818.001).
  • [ISSN] 1534-6285
  • [Journal-full-title] Current urology reports
  • [ISO-abbreviation] Curr Urol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 37
  •  go-up   go-down


5. Awasthi S: Next generation of human vaccines: what does the future hold? Hum Vaccin; 2008 Sep-Oct;4(5):344-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Next generation of human vaccines: what does the future hold?
  • The World Vaccine Congress was held in Arlington, VA April 21st-24th, 2008.
  • He discussed the government's plan to deliver a strategic outlook and follow a road map for vaccine development.
  • In an electrifying keynote address Gregory Poland, Professor of Medicine and Infectious Diseases at the Mayo Clinic in Rochester, MN discussed the role of recent advancements in the fields of Immunology, Genetics, Molecular Biology, Bioinformatics and the completion of the Human Genome Project.
  • Poland described the recent emergence of the field of Vaccinomics and laid out his vision for an era of personalized medicine.
  • Next-generation vaccine approaches targeting cervical cancer, meningitis, childhood diarrhea and renal cell carcinoma were presented by leaders in the field.
  • Preclinical and early-stage clinical successes of vaccines against Malaria, TB and Ebola were discussed along with a road map for HIV, TB and Malaria vaccine development.
  • [MeSH-major] AIDS Vaccines / immunology. Cancer Vaccines / immunology. Ebola Vaccines / immunology. Malaria Vaccines / immunology. Meningococcal Vaccines / immunology. Papillomavirus Vaccines / immunology. Rotavirus Vaccines / immunology. Tuberculosis Vaccines / immunology

  • MedlinePlus Health Information. consumer health - Ebola.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Malaria and HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18849649.001).
  • [ISSN] 1554-8619
  • [Journal-full-title] Human vaccines
  • [ISO-abbreviation] Hum Vaccin
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AIDS Vaccines; 0 / Cancer Vaccines; 0 / Ebola Vaccines; 0 / Malaria Vaccines; 0 / Meningococcal Vaccines; 0 / Papillomavirus Vaccines; 0 / Rotavirus Vaccines; 0 / Tuberculosis Vaccines
  •  go-up   go-down


6. Abdulla AB, Niloy AA, Shah TA, Biswas SK, Imran AK, Murshed KM, Ahmed M: Laurence Moon Bardet Biedl Syndrome. Mymensingh Med J; 2009 Jan;18(1 Suppl):S124-128
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical features appear early in childhood and diagnosis is usually done by puberty.
  • Prominent features include rod-cone dystrophy leading to blindness, postaxial polydactyly, central obesity, learning disability, hypogonadism in males and renal dysfunction.
  • Relatives with a single affected gene may have obesity, hypertension, diabetes and renal disease.
  • There is increased risk of renal cell carcinoma.
  • These include dietary modification, oral hypoglycaemic drugs, testosterone supplement etc.
  • Relatives of the patient should be screened for renal abnormality.


7. Rajasekaran SA, Huynh TP, Wolle DG, Espineda CE, Inge LJ, Skay A, Lassman C, Nicholas SB, Harper JF, Reeves AE, Ahmed MM, Leatherman JM, Mullin JM, Rajasekaran AK: Na,K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis. Mol Cancer Ther; 2010 Jun;9(6):1515-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have shown earlier that Na,K-ATPase beta(1)-subunit levels are highly reduced in poorly differentiated kidney carcinoma cells in culture and in patients' tumor samples.
  • In this study, we provide evidence that Na,K-ATPase is a new target of TGF-beta(1)-mediated EMT in renal epithelial cells, a model system used in studies of both cancer progression and fibrosis.
  • We further show that both Na,K-ATPase alpha- and beta-subunit levels are highly reduced in renal fibrotic tissues.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Oct 13;103(2):295-309 [11057902.001]
  • [Cites] Mol Biol Cell. 2001 Dec;12(12):3717-32 [11739775.001]
  • [Cites] Mol Biol Cell. 2001 Feb;12(2):279-95 [11179415.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2003 Jan;12(1):25-9 [12496662.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12537-45 [12560323.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1859-68 [12673711.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 May;284(5):F911-24 [12505862.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jun;284(6):C1497-507 [12570983.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21113-23 [12665527.001]
  • [Cites] J Cell Biol. 2003 Jun 9;161(5):979-89 [12782686.001]
  • [Cites] Am J Physiol Renal Physiol. 2003 Sep;285(3):F388-96 [12890662.001]
  • [Cites] Development. 2003 Oct;130(20):4963-74 [12930776.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1776-84 [14679171.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):1364-73 [14699059.001]
  • [Cites] FEBS Lett. 2004 Apr 9;563(1-3):151-4 [15063740.001]
  • [Cites] Am J Physiol Renal Physiol. 2004 Oct;287(4):F658-64 [15187003.001]
  • [Cites] Pancreas. 2004 Oct;29(3):e77-83 [15367897.001]
  • [Cites] Anal Biochem. 1975 Oct;68(2):537-44 [1200353.001]
  • [Cites] Nature. 1985 Aug 22-28;316(6030):691-5 [2993903.001]
  • [Cites] Nature. 1986 May 22-28;321(6068):429-31 [3012356.001]
  • [Cites] Cell. 1996 Feb 9;84(3):345-57 [8608588.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4250-60 [9250668.001]
  • [Cites] J Urol. 1999 Aug;162(2):574-80 [10411090.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):28-36 [10487609.001]
  • [Cites] J Cell Biol. 1963 May;17:375-412 [13944428.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2796-801 [15705719.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1071-81 [15616198.001]
  • [Cites] Dev Biol. 2006 Jan 15;289(2):406-19 [16356488.001]
  • [Cites] Mol Biol Cell. 2006 Apr;17(4):1871-9 [16467384.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8319-26 [16951136.001]
  • [Cites] Development. 2007 Jan;134(1):147-55 [17164420.001]
  • [Cites] J Mol Biol. 2007 Jan 19;365(3):706-14 [17078968.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G124-33 [16959951.001]
  • [Cites] J Cell Biol. 2007 Jan 15;176(2):223-30 [17227894.001]
  • [Cites] J Biol Chem. 2007 Apr 20;282(16):12127-34 [17317668.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):187-95 [17448872.001]
  • [Cites] J Pathol. 2007 Jun;212(2):170-9 [17471453.001]
  • [Cites] J Cell Biol. 2007 Jul 30;178(3):437-51 [17646396.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):954-60 [17632505.001]
  • [Cites] J Urol. 2008 Jan;179(1):338-45 [18006011.001]
  • [Cites] Histol Histopathol. 2008 Apr;23(4):459-67 [18228203.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:2130-48 [19273189.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1420-8 [19487818.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1429-37 [19487819.001]
  • [Cites] Nature. 2009 Jun 25;459(7250):1141-5 [19553998.001]
  • [Cites] Pediatr Nephrol. 2000 Dec;15(3-4):290-301 [11149129.001]
  • (PMID = 20501797.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK056216-09; United States / NIDDK NIH HHS / DK / R01 DK056216; United States / NIDDK NIH HHS / DK / R01 DK056216-09; United States / NIDDK NIH HHS / DK / R01-DK56216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Subunits; 0 / Transforming Growth Factor beta; 9NEZ333N27 / Sodium; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  • [Other-IDs] NLM/ NIHMS194853; NLM/ PMC2884047
  •  go-up   go-down


8. Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, Collins MH: Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer; 2008 Apr 1;112(7):1607-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation renal cell carcinoma: lack of negative impact due to lymph node spread.
  • BACKGROUND: Pediatric renal cell carcinoma (RCC) is clinically distinct from adult RCC.
  • Characterization of the unique biological and clinical features of pediatric RCC are required.
  • METHODS: A retrospective review and biological analysis of all RCC cases presenting to Cincinnati Children's Hospital Medical Center (CCHMC) in the last 30 years was undertaken.
  • A literature review of pediatric TFE+ cases was performed.
  • RESULTS: Eleven cases of RCC with clinical data were identified in our institutional review as follows: 6 clear cell, 2 papillary, 2 translocation, and 1 sarcomatoid.
  • Seven of 8 TFE+ RCC patients presented with TNM Stage III/IV disease.
  • Literature analysis confirmed a significant increase in advanced stage presentation in pediatric TFE+ RCC compared with TFE- RCC.
  • Fourteen of fifteen (93.3%) patients with TFE+ stage III/IV RCC due to lymph node spread (N+ M(0)) remain disease free with a median and mean follow-up of 4.4 and 6.3 years, respectively (range, 0.3-15.5).
  • CONCLUSIONS: Translocation morphology RCC is the predominant form of pediatric RCC, associated with an advanced stage at presentation.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Lymph Nodes / pathology. Translocation, Genetic
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / secondary. Adolescent. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Leucine Zippers. Lymphatic Metastasis. Male. Microphthalmia-Associated Transcription Factor / genetics. Neoplasm Proteins / genetics. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278810.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / MITF protein, human; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins; 0 / TFE3 protein, human; 0 / TFEB protein, human
  •  go-up   go-down


9. Spreafico F, Collini P, Terenziani M, Marchianò A, Piva L: Renal cell carcinoma in children and adolescents. Expert Rev Anticancer Ther; 2010 Dec;10(12):1967-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma in children and adolescents.
  • Although rare in children and adolescents, renal cell carcinomas (RCCs) raise important questions concerning the best treatment approach and accurate pathologic classification.
  • The differences emerging between childhood and adulthood RCC probably prevent any direct generalized application of therapies to children that are validated for adults.
  • The translocation type of RCC, which forms a distinct category characterized by translocations involving Xp11.2 or, less frequently, 6p21, has recently emerged as the predominant type of RCC in children and adolescents, whereas it is rarely diagnosed in adults.
  • Nephron-sparing surgery is currently recommended in adults for selected small-volume tumors, but additional data are needed before this experience can be extensively transferred to the pediatric population.
  • The backbone of systemic therapies for adult RCC has recently been changed by the introduction of drugs designed to target tumor-related angiogenesis and signal transduction.
  • It is worth noting that the largest clinical efficacy trials on targeted molecules have been conducted on clear-cell RCC.
  • While targeted drugs have become the standard of care for adult metastatic RCC, there are currently no published reports on their role in children, and their use should be considered for patients with unresectable metastatic or advanced-stage RCC.
  • [MeSH-major] Carcinoma, Renal Cell / therapy. Kidney Neoplasms / therapy. Nephrectomy / methods
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Agents / pharmacology. Child. Drug Delivery Systems. Humans. Lymph Node Excision / methods. Nephrons / surgery

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21110762.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement